The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity <it>in vitro</it>: a mechanism of action study
<p>Abstract</p> <p>Background</p> <p>Tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), and efavirenz (EFV) are the three components of the once-daily, single tablet regimen (Atripla) for treatment of HIV-1 infection. Previous cell culture studies have demonstrat...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2009-05-01
|
Series: | Retrovirology |
Online Access: | http://www.retrovirology.com/content/6/1/44 |